TICKERNERD
Menu
TVTXTVTXHealthcare · Biotechnology

TVTX Stock Forecast: Travere Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$57
+0.12% on the day

The 15 Wall Street analysts covering Travere Therapeutics, Inc. hold a median 12-month price target of $76 — +32.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 3 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$5.4B
Ticker Nerd rank
86 / 100
Median analyst target
$76
Analysts covering
15
Revenue$169.6M+48.2% y/y
Operating income$4.0M
Net income−$34.8M
Free cash flow$37.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−15.3%
YTD
+49.0%
1Y
+135.0%
From 52W high
−15.7%
From 52W low
+135.0%
$24
$68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TVTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Travere Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Momentum
94
Value
93
Growth
81
Accruals
77
Revisions
64
Volatility
46
Size
22
Issuance
11

Quality (99): The business earns solid, repeatable profits on what it owns.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26TVTXHigh $90Median $76Low $62

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $62Median $76High $90

The green dot is the last close — the median target sits +32.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026GuggenheimMaintainsBuy$75 → $89
22 Sept 2026HC Wainwright & Co.ReiteratesBuy$67
22 Sept 2026WedbushReiteratesOutperform$76
10 Aug 2026Evercore ISI GroupMaintainsOutperform—
10 Aug 2026Evercore ISI GroupMaintainsOutperform$68 → $78
6 Aug 2026Canaccord GenuityMaintainsBuy$62 → $70
6 Aug 2026Canaccord GenuityMaintainsBuy—
6 Aug 2026WedbushMaintainsOutperform$61 → $75
6 Aug 2026WedbushMaintainsOutperform—
5 Aug 2026CitigroupMaintainsBuy$70 → $85
5 Aug 2026CitigroupMaintainsBuy—
5 Aug 2026Evercore ISI GroupMaintainsOutperform$60 → $68
5 Aug 2026Evercore ISI GroupMaintainsOutperform—
5 Aug 2026GuggenheimMaintainsBuy—
5 Aug 2026GuggenheimMaintainsBuy$65 → $75
5 Aug 2026TD CowenMaintainsBuy—
5 Aug 2026TD CowenMaintainsBuy$60 → $75
30 July 2026Canaccord GenuityMaintainsBuy$56 → $62
30 July 2026Canaccord GenuityMaintainsBuy—
25 June 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TVTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Travere Therapeutics, Inc. returned +135.0% against +16.2% for the S&P 500, dividends included.

TVTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26TVTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.8%
Analysts raising
2
Analysts cutting
2
Fundamentals

Travere Therapeutics, Inc. (TVTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−196.3×

Cheaper than 99% of US stocks

Price / sales
9.1×

Cheaper than 15% of US stocks

Price / book
219.0×

Cheaper than 1% of US stocks

EV / EBITDA
239.8×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
48.2%

Higher than 86% of US stocks

Earnings growth (YoY)
48.2%

Higher than 74% of US stocks

Gross margin
94.6%

Higher than 98% of US stocks

Operating margin
2.3%

Higher than 49% of US stocks

Net margin
−7.3%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−236.4%

Higher than 6% of US stocks

Return on assets
−3.7%

Higher than 34% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Travere Therapeutics, Inc. (TVTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Travere Therapeutics, Inc. has a market value of $5.4B and an enterprise value of $5.5B.

  • Revenue in the twelve months to 30 June 2026: $591.3M. The latest quarter grew 48.2% year on year.

  • Net income over the same four quarters: −$43.5M, a −7.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.46.

  • Free cash flow in the twelve months to 30 June 2026: $15.2M.

  • Shares outstanding: 94.2M.

  • Trailing P/E: −196.3×; forward P/E: 10.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Travere Therapeutics, Inc. employs 497 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

TVTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TVTXTravere Therapeutics, Inc.$5.4B
86
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
CRSPCRISPR Therapeutics AG$5.3B
37
COGTCogent Biosciences, Inc.$5.3B
34
PTCTPTC Therapeutics, Inc.$5.3B
64
ORKAOruka Therapeutics, Inc.$5.6B
40
KODKodiak Sciences, Inc.$5.7B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Travere Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TVTX news & analysis

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Business Wire · 2 Oct 2026positive

Travere Therapeutics announced it will present nine new data presentations, including five oral presentations, on FILSPARI (sparsentan) in IgA nephropathy and focal segmental glomerulosclerosis at the American Society of Nephrology Kidney Week 2026 in Denver, October 21-25.

Why it matters — The new data, including the final SPARTAN analysis, could provide additional clinical evidence supporting FILSPARI's role as a treatment option in these kidney conditions.

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Business Wire · 23 Sept 2026positive

Travere Therapeutics announced that the USPTO issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, directed to certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods related to the drug.

Why it matters — A Travere watcher would care because the patent allowance is expected to extend U.S. patent coverage for FILSPARI in FSGS, potentially supporting the product's long-term commercial position.

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Business Wire · 21 Sept 2026neutral

Travere Therapeutics announced that Eric Dube, Ph.D., is stepping down as president and chief executive officer to focus on his health and family. The Board has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, to succeed him.

Why it matters — A leadership transition at the CEO level introduces uncertainty about the company's strategic direction and management continuity for TVTX stakeholders.

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Business Wire · 17 Sept 2026neutral

Travere Therapeutics announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. A live webcast will be available on the Investor page of Travere's website, with a replay accessible for up to 30 days after the event.

Why it matters — The upcoming forum presentation gives Travere Therapeutics watchers an opportunity to hear directly from company management about its work in rare diseases.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 11 Sept 2026neutral

Travere Therapeutics announced that on September 10, 2026, its Compensation Committee granted inducement restricted stock units to 16 new employees, covering an aggregate of 56,220 shares of common stock. The RSUs are subject to the terms of the company's 2018 Equity Incentive Plan but were granted outside that plan, in line with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The disclosure reflects Travere's equity-compensation practices for newly hired employees, a routine governance item that shareholders may track for potential dilution and hiring activity.

FAQ

Frequently asked questions about TVTX stock

What is the TVTX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Travere Therapeutics, Inc. have a median 12-month price target of $76, with estimates ranging from $62 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TVTX stock a buy right now?

Of the 15 analysts covering Travere Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Travere Therapeutics, Inc. 86 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TVTX?

As at 3 Oct 2026, Travere Therapeutics, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will TVTX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +32.6% from the last close, and Ticker Nerd's factor model ranks Travere Therapeutics, Inc. 86 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TVTX stock forecast for 2030?

No analyst covering Travere Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $90 over the next 12 months.

How has TVTX stock performed over the past year?

Travere Therapeutics, Inc. returned +135.0% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Travere Therapeutics, Inc. do?

Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases.

What is the latest news on TVTX?

The most recent item we track (Business Wire, 2 Oct 2026): "Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026". Travere Therapeutics announced it will present nine new data presentations, including five oral presentations, on FILSPARI (sparsentan) in IgA nephropathy and focal segmental glomerulosclerosis at the American Society of Nephrology Kidney Week 2026 in Denver, October 21-25.

Company

About Travere Therapeutics, Inc.

Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases. Its current commercial portfolio includes FILSPARI, a treatment for certain kidney disorders, along with legacy rare-disease products such as Thiola, Thiola EC, Cholbam, and Chenodal. The company also supports specialized care through disease-focused programs and physician engagement aimed at addressing conditions with limited treatment options. Travere Therapeutics Inc. serves patients, healthcare providers, and rare-disease communities across its core therapeutic areas, combining approved medicines with ongoing development work in nephrology and metabolic disease. Headquartered in San Diego, California, Travere Therapeutics Inc. plays a notable role in the rare-disease biopharmaceutical market through its focused product set and concentrated clinical expertise.

CEO Dr. Eric M. Dube Ph.D. · 497 employees · United States · https://travere.com